Despite this, there was no significant difference in SARS-CoV-2 IgA and SARS-CoV-2 IgG antibody levels among JIA patients with active disease (JADAS 71 >1), those with inactive disease (JADAS 71 ≤1), and healthy controls. This evidence concerns the gene CD79A and juvenile idiopathic arthritis.